Analyst Reco. Allogene Therapeutics, Inc.

Equities

ALLO

US0197701065

Real-time Estimate Cboe BZX Other stock markets 03:36:04 2024-05-23 pm EDT			5-day change	1st Jan Change
2.545 ^USD	-4.32%		-15.78%	-21.03%

May. 21	Oppenheimer Trims Allogene Therapeutics Price Target to $13 From $14, Maintains Outperform Rating	MT
May. 16	HC Wainwright Adjusts Price Target on Allogene Therapeutics to $9 From $10, Keeps Buy Rating	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Oppenheimer Trims Allogene Therapeutics Price Target to $13 From $14, Maintains Outperform Rating	May. 21	MT
HC Wainwright Adjusts Price Target on Allogene Therapeutics to $9 From $10, Keeps Buy Rating	May. 16	MT
Stifel Adjusts Price Target on Allogene Therapeutics to $4.60 From $4.40, Keeps Hold Rating	May. 14	MT
B. Riley Adjusts Price Target on Allogene Therapeutics to $7 From $10, Keeps Buy Rating	May. 14	MT
Allogene Therapeutics Prices $110 Million Offering	May. 13	MT
HC Wainwright Adjusts Allogene Therapeutics Price Target to $10 From $12, Maintains Buy Rating	Jan. 19	MT
B. Riley Adjusts Allogene Therapeutics' PT to $10 From $15 on Heels of Announced Strategic Shift to Focus on New Study for Large B-cell Lymphoma, Keeps Buy Rating	Jan. 05	MT
JMP Securities Downgrades Allogene Therapeutics to Market Perform From Market Outperform	Jan. 05	MT
Citigroup Starts Allogene Therapeutics With Buy Rating, $7 Price Target	Dec. 08	MT
HC Wainwright Cuts Price Target on Allogene Therapeutics to $12 From $23, Keeps Buy Rating	Nov. 15	MT
JPMorgan Adjusts Allogene Therapeutics Price Target to $9 From $11, Maintains Overweight Rating	23-09-25	MT
Truist Securities Lowers Allogene Therapeutics' Price Target to $18 From $20, Maintains Buy Rating	23-07-11	MT
RBC Lowers Allogene Therapeutics' Price Target to $12 From $15, Keeps Outperform Rating	23-07-07	MT
JMP Securities Adjusts Allogene Therapeutics' Price Target to $15 From $19, Keeps Outperform Rating	23-05-05	MT
Stifel Nicolaus Adjusts Allogene Therapeutics Price Target to $7.50 From $8, Maintains Hold Rating	23-05-04	MT
RBC Capital Adjusts Allogene Therapeutics Price Target to $15 From $22, Maintains Outperform - Speculative Risk Rating	23-04-06	MT
HC Wainwright Adjusts Price Target on Allogene Therapeutics to $23 From $29, Maintains Buy Rating	23-04-04	MT
Bernstein Initiates Allogene Therapeutics at Market Perform With $6 Price Target	23-03-21	MT
JMP Securities Adjusts Price Target on Allogene Therapeutics to $19 From $23, Maintains Market Outperform Rating	23-03-02	MT
Oppenheimer Adjusts Allogene Therapeutics Price Target to $28 From $32, Maintains Outperform Rating	23-03-01	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Allogene Therapeutics, Inc.

Equities

ALLO

US0197701065

Analyst Reco.

Filters